Trial · NCT05261997
Endotherapy for Painless Chronic Pancreatitis
NCT05261997, Not applicable, Unknown, Changhai Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Endotherapy for Painless Chronic Pancreatitis. Trials, record NCT05261997. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05261997
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Endotherapy for Painless Chronic Pancreatitis
- NCT number
- NCT05261997
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Changhai Hospital
- Conditions
- Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency, Abdominal Pain, Cholangiopancreatography, Endoscopic Retrograde
- Interventions
extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct, pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)
- First posted
- 2022-03-02
- Last updated
- 2022-03-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | exocrine function of the pancreas assessed by the value of fecal elastase in μg/g | 12 months | Pancreatic exocrine function insufficiency(PEI) is defined as fecal elastase \<200 μg/g. The result wii be divided into 4 conditions, including normal exocrine function, newly developed PEI, PEI relief, PEI persisting. |
| Secondary | endocrine function of the pancreas assessed by glycosylated hemoglobin in %. | 12 months | It is considered as pancreatic endocrine function insufficiency when glycosylated hemoglobin \>6.5%， the result of pancreatic endocrine function can also be divided into 4 parts similar to that of pancreatic exocrine function. |
| Secondary | endocrine function of the pancreas assessed by fasting blood glucose in mmol/L | 12 months | It is considered as pancreatic endocrine function insufficiency when fasting blood glucose \>6.1mmol/L, the result of pancreatic endocrine function can also be divided into 4 parts similar to that of pancreatic exocrine function. |
| Secondary | endocrine function of the pancreas assessed by fasting C peptide in ug/L | 12 months | It is considered as pancreatic endocrine function insufficiency when fasting C peptide\<1.1ug/L, the result of pancreatic endocrine function can also be divided into 4 parts similar to that of pancreatic exocrine function. |
| Secondary | life quality assessed by SF-36 questionnaire | 12 months | life quality assessed by the MOS item short from health survey (SF-36) questionnaire |
| Other | BMI in kg/m^2 | 12 months | Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters. |
| Other | Treatment-related costs in RMB from initial enrollment to the end of the study | 12 months | The total costs in RMB of each hospitalization |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05261997
GET https://conductscience.org/api/trials/v1/NCT05261997/registered